H1 20: soft guidance takes centre stage
14/08/20 -"Novozymes reported largely in line Q2 20 numbers as sales were down 2% (in line with the trading update) and the EBIT margin came in at 25.9% (-10bp vs trading update). The key takeaway was the ..."
Pages
60
Language
English
Published on
14/08/20
You may also be interested by these reports :
27/08/26
While immense pricing and competitive pressures from Eli Lilly and compounding pharmacies have proven to be a nightmare for Novo Nordisk in the last ...
26/08/26
We upgrade Novonesis to ADD from Reduce. The Q2 26 results marked a clear inflection point: broad-based organic growth (+9%, well ahead of consensus) ...
24/08/26
Q2 profitability beat expectations; however, the top line lagged consensus. The quarterly growth was driven by strong performance in LatAm, Animal ...
21/08/26
The H1 profitability surpassed consensus, though sales matched expectations. The Branded segment was the sole driver of sales growth in H1, though ...